← Back to DNTH

Dianthus Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 04/08/2026Mar 2026Filed 04/08/2026Sep 2025Filed 05/11/2025Jun 2025Filed 04/08/2026Mar 2025Filed 04/08/2026Sep 2024Filed 05/11/2025Jun 2024Filed 05/11/2025Mar 2024Filed 05/11/2025
$12$6.3$0.4$0.2$1.2$2.2$1.9$0.9
−$50−$41−$37−$32−$30−$25−$18−$14
−$0.90−$0.85−$0.97−$0.88−$0.82−$0.74−$0.51−$0.54
5648383636343426

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.